Indian Cancer Drug Prices: Supreme Court Ruling Triggers 70% Price Cut
New regulations cap trade margins on 137 medications following a landmark legal challenge, aiming to reduce annual patient spending by 199 million pounds.
By Youssef Carter ·

The Indian government will lower the cost of 137 cancer medicines starting next month. This move follows a Supreme Court ruling that labeled existing hospital markups as extortion. The decision directly addresses the financial crisis faced by patients who often skip treatment or sell assets to pay for care.
The regulatory change extends a 30% cap on trade margins to a wider range of drugs. Previously, this limit applied to only 42 medications. The National Pharmaceutical Pricing Authority analyzed the market and found average trade markups on some cancer drugs reached 170%. In extreme cases, the markup exceeded 700%. One specific drug sold to hospitals for 2,700 rupees was listed at 27,000 rupees for patients.
The legal battle began with Sarojam Radhakrishnan, a retired bank clerk from Kerala. Diagnosed with breast cancer in 2021, she faced monthly treatment costs exceeding 63,000 rupees. Her family could not afford this amount, so she petitioned the Kerala high court in 2022. The case eventually reached the Supreme Court, where justices Vikram Nath and Sandeep Mehta reviewed the pricing structures.
The Department of Pharmaceuticals stated the new measure is expected to cut medicine prices by up to 70%. This reduction should help cancer patients save approximately 2,500 crore rupees, or 199 million pounds, annually. The goal is to lower out-of-pocket expenses for families managing chronic illness.
Medical experts note that high costs deter many from seeking care. Krishan Kalra, a former council member of the Rajiv Gandhi Cancer Institute, observed that few people attend free diagnosis camps. Patients fear the diagnosis because they lack funds for treatment. Cancer drugs currently range from 38,000 to 380,000 rupees. Studies indicate that healthcare spending pushes about 55 million Indians below the poverty line each year.
Government insurance schemes offer limited protection. The Ayushman Bharat scheme provides 500,000 rupees in annual coverage per family. This amount equals the cost of one dose of Kadcyla, a breast cancer drug. Patients may require up to 14 doses of that medication. Dr. Ravi Kannan, a surgical oncologist in Assam, called the new decision a welcome step for accessibility.
India records roughly 1.56 million new cancer cases annually. Jyotsna Singh, co-convener of the Working Group on Access to Medicines, argued that a total overhaul of healthcare is needed. She warned that hospitals might raise other charges to offset lower drug prices. The Supreme Court has asked the government to justify why the cap applies only to cancer drugs. The government must respond by 27 October. Radhakrishnan died in September 2022 while her case was pending.






